Provided by Tiger Trade Technology Pte. Ltd.

Agenus

8.09
+0.60008.01%
Post-market: 8.170.0800+0.99%19:45 EDT
Volume:1.52M
Turnover:12.14M
Market Cap:364.22M
PE:3.24
High:8.35
Open:7.58
Low:7.58
Close:7.49
52wk High:8.85
52wk Low:2.71
Shares:45.02M
Float Shares:42.21M
Volume Ratio:1.10
T/O Rate:3.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.50
EPS(LYR):-0.0034
ROE:-1278.83%
ROA:12.53%
PB:-1.83
PE(LYR):-2,382.21

Loading ...

Agenus Secures up to $340 Mln to Advance Colon Cancer Drug into Late-stage Study; Shares Jump

Reuters
·
Jul 13

Agenus Issues Series A, Series B Warrants in USD 85 Million Private Placement

Reuters
·
Jul 13

Agenus - to Increase Board to Nine, Adding Two Directors Designated by Commodore Capital Master Lp

THOMSON REUTERS
·
Jul 13

Agenus Announces Oversubscribed Private Placement of up to $340 Million to Advance Registrational Robbin Trial of Neoadjuvant Bot+bal in Mss Colon Cancer

THOMSON REUTERS
·
Jul 13

Agenus - Discontinues Financial Support for Battman Phase 3 Study

THOMSON REUTERS
·
Jul 13

Agenus Issues 56,525 New Warrants, Sets SEC Resale Registration Deadline Within 90 Days

Reuters
·
Jul 07

Agenus' Potential Colorectal Cancer Combination Shows 21.2-Month Survival

MT Newswires Live
·
Jul 06

Agenus Reports Landmark Bot+bal Data Showing 33% Three-year Overall Survival in Refractory Mss Metastatic Colorectal Cancer Without Active Liver Metastases at Esmo Gi 2026

THOMSON REUTERS
·
Jul 06

Agenus to Present Three-year Survival Data from Bot+bal Phase 1b Study in MSS Metastatic Colorectal Cancer at ESMO GI 2026

Reuters
·
Jun 25

Agenus Shareholders Approve Governance, Compensation and Auditors

TIPRANKS
·
Jun 23

Agenus shareholders approve 5 million-share increase to 2019 equity plan at annual meeting

Reuters
·
Jun 23

Agenus Nears Key Readout as Botensilimab Pancreatic Cancer Trial Reaches Completion

TIPRANKS
·
Jun 12

Agenus announces virtual annual shareholders meeting

Reuters
·
Jun 03

Backlash over Trump's $1.776 billion fund tests Blanche's bid for US attorney general

Reuters
·
May 29

Agenus reports Phase 2 BOT+BAL melanoma trial shows 22% response rate

Reuters
·
May 22

Agenus says AI model predicts BOT+BAL response, survival in MSS metastatic colorectal cancer

Reuters
·
May 22

Agenus Announces Resignation of Principal Accounting Officer

TIPRANKS
·
May 16

Agenus announces publication of Phase 1b BOT+BAL data

TIPRANKS
·
May 16

Agenus principal accounting officer Charette resigns effective May 29

Reuters
·
May 16

Agenus reports Phase 1b BOT+BAL trial shows 17% response in post-immunotherapy HCC

Reuters
·
May 16